Alto Neuroscience has reported positive results from its Phase I clinical trial of the PDE4 inhibitor, ALTO-101, for treating cognitive impairment associated with schizophrenia (CIAS).
The study demonstrated that ALTO-101, when administered through a transdermal delivery system (TDS), had a favourable tolerability and improved pharmacokinetics compared to oral administration.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase I study was designed to assess the safety, tolerability, pharmacokinetics, and adhesion properties of ALTO-101’s transdermal formulation, compared to its oral administration, in healthy volunteers.
Alto enrolled 15 participants aged between 40 and 64 in the study, which involved a two-way crossover design, with two dosing periods.
The first period included a single oral dose of 1mg ALTO-101, followed by a seven-day washout period. In the second period, participants received an 18mg transdermal dose of ALTO-101 for two days.
The results indicated that transdermal administrations of ALTO-101 led to significantly higher and more consistent drug concentrations than oral administration.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition, the transdermal delivery of ALTO-101 resulted in substantially lower class-related adverse events typically associated with PDE4 inhibitors.
These findings suggest that ALTO-101 has a favourable profile with higher drug exposure levels within the therapeutic range and lower rates of adverse events.
Alto Neuroscience founder and CEO Amit Etkin said: “These positive results provide a strong indication that ALTO-101 could become an important therapeutic option for a broad range of indications.
“Oral PDE4 inhibitors have shown promise as pro-cognitive therapeutics but are associated with burdensome and dose-limiting side effects.
“We have now demonstrated transdermal administration of ALTO-101 results in significantly greater, stable drug concentration with a once-daily formulation that is well-tolerated. We look forward to advancing this product candidate for patients with CIAS who currently have few treatment options.”
ALTO-101 is being developed specifically for CIAS, a condition with no targeted treatments currently available.
Earlier this month, Alto Neuroscience started Phase II clinical trial of histamine H3 receptor inverse agonist, ALTO-203, for treating patients with major depressive disorder (MDD).
